Tuesday, December 15, 2020, 8:00 AM PST
LOS ANGELES – National Research Institute (NRI) has announced today plans to participate in an observer blinded, placebo-controlled clinical trial against COVID-19. The Phase 3 study is sponsored by Novavax, Inc. with NVX-CoV2373 vaccine candidate. Novavax, Inc. is a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases.
NRI’s Chief Medical Officer, Mark Leibowitz, M.D., is the Principal Investigator and will lead this study program along Fernanda Morales, Senior Project Manager. Dr. Leibowitz shares, “We are excited to be a participating research center in the development of this potentially life-saving vaccine against SARS-CoV-2. With your interest, help and community spirit, we hope that our efforts will be fruitful and contribute to reducing the impact of this virus.”
The study is part of a larger, global clinical program that will prioritize the at-risk population and plans to enroll 30,000 participants worldwide. People interested in participating in the study through the National Research Institute site can visit https://nritrials.com/covid-study/ or call 1-877-720-8484 to find out more.
NVX-CoV2373 is a prefusion protein coronavirus vaccine candidate made using Novavax’s proprietary nanoparticle technology, Matrix-M, which is an adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies.
About National Research Institute
National Research Institute’s mission is to provide access to innovative therapies and to bring hope to our community through clinical research. Our multi-disciplinary and multi-cultural organization ensures the utmost commitment to patient care, safety, and well-being. Located in Los Angeles, Huntington Park, Panorama City, and Santa Ana, NRI has conducted clinical trials for over 30 years. Our patients have benefited from participating in the advancement of life-saving medicines, many of which are now commercially available.
National Research Institute Contacts
Mark Leibowitz, M.D. Chief Medical Officer
Samira Moran, President & CEO